Objective: There has been a significant decrease in the number of published reports of classical polyarteritis nodosa (PAN) in the post-Chapel Hill consensus conference (CHCC) nomenclature era with only two series published from Asia. We report a case series of PAN from north India.
INTRODUCTION
Polyarteritis nodosa (PAN) is a systemic necrotizing vasculitis of medium vessels, first described by Kussmaul and Meyer in 1866. Initial reports of PAN included cases currently classified as microscopic polyangiitis (MPA) according to the Chapel Hill consensus conference nomenclature system (CHCC). 1 In the post-CHCC era, there have been very few published case series of PAN and it is now considered a rare disease entity. Infection with hepatitis B virus (HBV) is a known etiological agent in PAN and the decrease in the occurrence of hepatitis B due to vaccination is another factor contributing to declining incidence. 2 Untreated disease has a dismal prognosis with a 5-year survival of 13%. 3 The prognosis of the disease has markedly improved with the use of immunosuppressive therapy. 4, 5 However, the ideal duration of therapy is still debatable in the absence of controlled trials and the treatment outcomes are not known in patients from South-east Asia. India has intermediate endemicity of hepatitis B, but very few cases of PAN have been reported from India. 6 The previous studies from France have shown differences in the clinical presentation between HBV-associated PAN and non-HBV-associated PAN. 5 We report the clinical presentations and outcomes based upon HBV status in patients with PAN seen at a tertiary care centre in north India.
MATERIALS AND METHODS
Study design: cross-sectional, retrospective, observational study Setting Rheumatology clinic in a tertiary care centre in north India with annual hospital outpatient registrations of around 2.2 billion.
Population
Patients aged > 18 years of age seen under rheumatology services diagnosed as PAN based on American College of Rheumatology (ACR)/CHCC criteria.
Methodology
Diagnosis of PAN was made by a rheumatologist according to ACR/CHCC criteria. The duration of the study was from January 2005 to December 2015. Clinical details, investigations and treatment outcomes were retrieved from medical records. Renal involvement was defined as accelerated or new onset hypertension, elevated creatinine > 1.3 mg/dL, 24-h urine protein of ≥500 mg on quantification and/or hematuria. In patients with neurological involvement, the details of neurological involvement, investigations such as nerve conduction velocity, nerve biopsy were recorded. The details of computed tomography (CT) angiographic findings of the patients were also noted. Five factor score (FSS: both conventional and revised 7 ) was calculated for all patients at the initial presentation. The details of treatment in the form of immunosuppressive therapy and plasmapheresis were also noted. Anti-neutrophil cytoplasmic antibody (ANCA) testing was done for all patients using indirect immunofluorescence. Hepatitis B surface antigen was tested in all patients using enzyme-linked immunosorbent assay. The characteristics of HBV-related PAN were compared with patients with non-HBV-related PAN. Ethics clearance was taken from the institutional ethics committee and guidelines set by the Indian Council of Medical Research (1994) and Helsinki Declaration (modified, 1989) were adhered to.
Statistical analysis
Statistical analysis was performed using IBM SPSS Statistics (version 22.0; IBM, Armonk, NY, USA). Descriptive data are given as the mean AE standard deviation (SD), or as the median and interquartile range (IQR). The Chi-square test or Fisher's exact test were used to compare dichotomous variables and the t-test or Mann-Whitney test were used for continuous variables, as appropriate. For all tests, a two-sided P-value of 0.05 or less was considered statistically significant. Survival rates were estimated using the Kaplan-Meir method.
RESULTS
Twenty-seven cases (20 male and seven female) were diagnosed as having PAN during the study period. All patients fulfilled the ACR criteria for PAN. Mean age at presentation was 38.4 AE 13.2 years. Seven patients (25.9%) were positive for hepatitis B surface antigen. None of the patients had hepatitis C or human immunodeficiency virus (HIV) positivity. The clinical features are summarized in Table 1 .
Neurological involvement
Twenty four patients had neurological involvement, making it the most common organ involved (88.9%). The details of various neurological involvements are given in Table 2 . Twenty-two patients (81.5%) had mononeuritis multiplex. Nerve biopsy was done in 10 patients and was consistent with vasculitis in seven patients. Central nervous system (CNS) involvement was observed in four patients with one patient having intracerebral bleed and three patients having cerebral infarcts. There was no difference in mortality in patients with and without neurological involvement (P = 0.746). However, patients with CNS involvement had a poorer outcome which was statistically significant (P = 0.027).
Renal involvement
Sixteen patients (59.3%) had renal involvement. Eleven (40.7%) had accelerated hypertension. Six (22.2%) had renal insufficiency at presentation with elevated creatinine. Two of these patients required dialysis. One of these patients had small-sized kidneys at the time of initial presentation suggestive of underlying chronic kidney disease with CT of the abdomen showing renal scars and the second patient developed sepsis with acute kidney injury resulting in his demise. Ten patients (37%) had proteinuria of > 500 mg on 24-h urine protein quantification. Two patients developed spontaneous perinephric hematomas, one at first presentation and one at the time of relapse. CT angiography of renal vessels was available in 12 of these and revealed abnormalities in nine: aneurysms in five, renal infarcts in four and renal scars in one. In three patients angiography did not reveal any abnormality in the kidneys.
Gastrointestinal involvement
Eight patients (29.6%) had symptomatic gastrointestinal involvement due to mesenteric ischemia. Six (22.2%) patients had history of abdominal pain. Two patients had upper gastrointestinal (GI) bleed and two had lower GI bleed. Two patients underwent laparotomy and bowel resection for gangrenous bowel. In both of these patients the resected surgical specimen confirmed vasculitis. CT angiography of the abdominal arteries was available in five and revealed aneurysms in two patients and stenosis in one patient, three of these had diffuse thickening of bowel loops suggestive of ischemia.
Others
Nine patients (33.3%) had cutaneous involvement. Seven of them had a purpuric rash, one had skin nodules and one had vasculitic ulcers. Skin biopsy was done in four and was consistent with vasculitis in three of them. Ten patients had musculoskeletal involvement in the form of arthralgias or myalgias. Digital gangrene was present in eight patients (29.6%). Six of the 20 male (30%) patients reported testicular pain. Testicular biopsy was done in one patient which revealed testicular infarct. Cardiac involvement in the form of dilated cardiomyopathy was present in four (14.8%) and there was clinical improvement with immunosuppresive therapy in all the patients. One patient had a relapse in cardiac dysfunction which responded to reinduction with intravenous methylprednisolosne and intravenous pulses of cyclophosphamide. Four patients also developed deep venous thrombosis (DVT) and one patient had chronic Budd-Chiari syndrome at presentation. 8 This patient had thrombosis of the hepatic and portal veins and was positive for antiphospholipid antibodies.
One patient with DVT presented with proteinuria and renal insufficiency 6 years after first presentation and biopsy revealed features of antiphospholipid antibodyassociated nephropathy. He also tested positive for lupus anticogulant. Both these patients fulfilled the Sydney criteria for antiphospholipid antibody syndrome.
Histological and angiographic confirmation of diagnosis
Fifteen biopsies were done in 14 patients: four skin, 10 nerve and one testicular biopsy. Of these, three skin, seven nerve and one testicular biopsy were consistent with vasculitis. Two patients who succumbed to illness underwent complete autopsy which confirmed the diagnosis of PAN. In two patients who underwent laparotomy the diagnosis was confirmed by histopathology of the resected bowel. Seventeen patients underwent CT angiography of the abdomen; of these 12 had either stenosis or aneurysms in renal or abdominal arteries (Fig. 1) . Two had normal findings, two had renal infarcts and one had non-occlusive mesenteric ischemia. The diagnosis was confirmed on histopathology or angiography in 21 patients.
Treatment
Twenty-five patients received immunosuppressive treatment. All of these were given high-dose steroids. 
One patient had both facial nerve palsy and posterior circulation stroke. Intravenous pulse cyclophosphamide was given in 17 patients and azathioprine was given in one patient for initial immunosuppression. Fourteen patients with non-HBV-related PAN were treated with monthly cyclophosphamide pulses followed by azathioprine for maintenance. Three patients were treated with steroids only, one was given azathioprine and two died before additional immunosuppression could be given. Six of the seven patients with HBV-related PAN were treated with steroids. One patient was managed with plasma exchange. Three were given cyclophosphamide pulses in view of active vasculitis as plasma exchange could not be done due to financial constraints. All of these patients also received antivirals. One patient refused treatment and went against medical advice.
Patients with digital gangrene due to vasculitis without demonstrable thrombosis did not receive anticoagulation. They were managed with immunosuppression and pain management. None of the patients had recurrence of gangrene. Patients with venous thrombosis were given anticoagulation for 6 months. Patients positive for antiphospholipid antibodies were given lifelong anticoagulation.
Outcome
Follow-up data were available in 26 patients. The overall mortality was 11.1%; all of them died during the first presentation. Two patients died of sepsis and one patient had suspected aneurysmal rupture which could not be confirmed. One patient had chronic kidney disease at the time of presentation which progressed to end-stage renal disease requiring maintenance hemodialysis. Of the seven patients with hepatitis Brelated PAN four patients are doing well, one developed chronic liver disease, one died and one was lost to follow-up. There was no difference in mortality between HBV-related and non-HBV-related PAN (P = 0.207). The cumulative survival was 114.16 months (95% CI: 98.27-129.95). There was no difference in the survival between HBV-and non-HBV-related PAN (Fig. 2) .
Five factor score
Eleven patients had a FFS of zero, 10 had a FFS of one, four had a score of two and two had a score of three. Both the FFS as well as the revised FFS showed no correlation with mortality (P = 0.248 for FFS, P = 0.894 for revised FFS). Patients with HBV-related PAN had lower FFS as compared with non-HBV-related disease (P = 0.039). Revised FFS did not differ between the two groups (P = 0.127).
DISCUSSION
Classic PAN involves medium-sized muscular arteries. It can also involve small arteries; however, it spares small vessels. Older series of PAN include patients currently classified as microscopic polyangiitis (MPA). 3, 4, 9 Subsequently, with the introduction of ANCA testing and CHCC nomenclature, MPA was identified as a separate entity.
1 Very few series of PAN have been published post-CHCC. 5 PAN may be idiopathic or be associated with specific triggers. Of these the most important etiological agent is hepatitis B, although rarely hepatitis C or HIV may also be associated with PAN. 2 With the introduction of vaccination for hepatitis B and screening of blood products, hepatitis B-associated PAN has become extremely rare in developed countries. Both the above factors have contributed to the declining incidence of PAN.
Polyarteritis nodosa is traditionally considered a rare disease in the Indian subcontinent. India has intermediate endemicity of hepatitis B with a population prevalence rate of around 3%. 10 However, only few cases of HBV-related PAN have been reported from India. In a previous series of viral hepatitis from Mumbai which included 181 patients with hepatitis B, six patients with PAN were reported. 6 In a previous series of 17 patients with PAN published from north India, none of the patients had HBV-related PAN.
11
Polyarteritis nodosa virtually involves any organ and has protean manifestations. Constitutional symptoms are extremely common with more than two-thirds reporting fever and weight loss. 5, 12 The commonest organ involved is neurological with peripheral nervous involvement being reported in 50-75% of patients. [3] [4] [5] Our series had higher neurological involvement compared to older series with PNS involvement being seen in 81.5% of patients. PNS involvement is commonly in the form of mononeuritis multiplex and peripheral symmetric neuropathy is rare.
5 CNS involvement was rare in our series which is similar to other series. CNS involvement in PAN may occur due to vasculitis or malignant hypertension and is associated with poor prognosis. 13 Renal involvement in PAN is usually in the form of hypertension due to intrarenal artery involvement without glomerulonephritis and is seen in half to two-thirds of patients.
14 In our series, 59% of patients had some form of renal involvement. However, only a small subset had renal insufficiency. The mild proteinuria might be because of ischemic glomerulopathy or underlying hypertension. Proteinuria was reported in 22% of the patients in the French vasculitis study group (FVSG) series of 348 patients. 5 GI involvement may occur in up to 50% of patients and is one of the most severe manifestations of PAN. 5, 14 As compared to older series, we had lower GI involvement. It is a major cause of death in the first year of disease. 15 It usually presents with abdominal pain and in severe cases may be associated with GI bleeding and perforation peritonitis. Rare features include cholecystitis and appendicitis. 5 Severe GI involvement is a poor prognostic feature included in the FFS. 13 Orchitis is a rare but characteristic manifestation of PAN and was present in 30% of our male patients which was higher than previous reported series.
14 Other uncommon manifestations were perinephric hematoma in two patients and DVT in five patients. Venous thrombosis has been reported in all vasculitides. Although venous thrombosis is less Two of these patients also tested positive for antiphospholipid antibodies. Antiphospholipid antibody syndrome is very rarely reported in PAN patients. 17 Clinical features in our series as compared to other series is summarized in Table 3 . We did not find any differences in the clinical manifestations between the HBV-related PAN and non-HBVrelated PAN groups probably due to smaller numbers. In a large series of 348 patients reported by Pagnoux et al., patients with HBV-related PAN (n = 123) had more frequent peripheral neuropathy, abdominal pain, cardiomyopathy, orchitis and hypertension compared with patients with non-HBV-related PAN (n = 225). Microaneurysms were more common in the mesenteric artery and not in the renal artery in HBV-associated PAN. Skin manifestations were less common in HBVassociated PAN. 5 We treated most of our patients with glucocorticoids and monthly cyclophosphamide pulses for 1 year. Most of our patients had excellent responses to this regimen with relatively few relapses. Studies done by the FVSG have suggested tailoring the treatment as per disease severity based on FFS. Although the overall survival for patients with FFS of 0 is excellent, results of a randomized trial of 124 patients of PAN and MPA showed that only 40% went into sustained remission with corticosteroids and 40% required additional immunosuppression. 18 The presence of mononeuritis multiplex in patients with FFS of 0 predicts the need for additional immunosuppressive therapy. 19 Patients with HBV-associated PAN were managed with short-course steroids, immunosuppression, plasmapheresis and antivirals. One patient developed chronic liver disease on followup despite use of antivirals. Due to the risk of promoting viral replication, currently HBV-related PAN is treated with short courses of corticosteroids and plasma exchanges along with antivirals. Plasma exchanges are stopped once seroconversion is achieved as HBV-associated PAN rarely relapses after seroconversion. 20 The FFS has been established as a prognostic index in PAN and higher FFS is associated with increased mortality. 13 We did not find any correlation between mortality and FFS in our series possibly due to small numbers. The mortality rate in our cohort was 11.1% (n = 3) which is similar to that reported by Gupta et al.
(17.64%, n = 4). In our study the FFS was significantly higher in non-HBV-related PAN as compared to HBVrelated PAN (P = 0.039). The cumulative survival and mortality did not differ between the two groups. This is in contrast to the findings of FVSG where HBV-related PAN had more severe disease and higher mortality. 5 Most of our patients responded well to cyclophosphamide and all deaths occurred in the first 3 months of illness due to uncontrolled disease and sepsis. We noted relapses in 18.5% of our patients and this was similar to the findings in previous series. 5 In addition, all the relapses occurred in non-HBV-related PAN, which is similar to other reported series where HBVrelated PAN has a very low relapse rate. 5, 20 There are some studies with no relapses and PAN is considered a monophasic disease. 11 However, studies done by the FVSG have shown relapses even in FFS 0 patients. The relapse rate in this study was similar to that of microscopic polyangiitis. 21 Limitation of our study include the retrospective design and relatively short duration of follow-up. Nerve biopsies could not be done in all patients with mononeuritis multiplex. Angiography data was not available in all patients.
In conclusion, PAN in our region is associated with higher neurological involvement and lower GI involvement. Clinical manifestations and outcomes of HBVrelated PAN were similar to non-HBV-related PAN. All the deaths in our series occurred at the first presentation. Prognosis was fair in most patients with low mortality and few relapses.
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